Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. (2021)
Attributed to:
Using MHC class I peptides to modulate NK cell activity, as a basis for immunotherapy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fonc.2021.785635
PubMed Identifier: 34926302
Publication URI: http://europepmc.org/abstract/MED/34926302
Type: Journal Article/Review
Volume: 11
Parent Publication: Frontiers in oncology
ISSN: 2234-943X